New Rule Might Increase Out-of-Pocket Drug Costs for Patients
Patients may face increased out-of-pocket drug costs as a result of a rule finalized by the Centers for Medicare & Medicaid Services in July 2020.
prescription drug spending
-
Read more: New Rule Might Increase Out-of-Pocket Drug Costs for Patients -
Read more: 3 Challenges to Patents on Therapeutic Monoclonal Antibodies 3 Challenges to Patents on Therapeutic Monoclonal Antibodies
Three developments may have effects on the use of patents to fend off competition for therapeutic monoclonal antibodies.
-
Read more: AbbVie Wins First Round in Humira Antitrust Lawsuit AbbVie Wins First Round in Humira Antitrust Lawsuit
The purpose of the secondary patent filings was to assemble a thicket of patents, 132 in all, to prohibit competition from biosimilar companies.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Selections feature topics ranging from political pressures facing the FDA, to the financial incentive structure for antibiotic development.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on pharma, health law, and policy issues from August 2020.
-
Read more: The Promise and Pitfalls of Trump’s “Most Favored Nation” Approach to Drug Pricing The Promise and Pitfalls of Trump’s “Most Favored Nation” Approach to Drug Pricing
A recent executive order aimed at addressing ballooning pharmaceutical expenditures is ambitious in scope, but its impact remains to be seen.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from July 2020.
-
Read more: To Cut Prescription Drug Spending, Stop Delays for Generic Competition To Cut Prescription Drug Spending, Stop Delays for Generic Competition
While generic competition is crucial for reducing drug prices, brand-name drug manufacturers can utilize several strategies to delay such competition.
-
Read more: How Policies Enacted During COVID-19 Might Reduce Future Drug Spending How Policies Enacted During COVID-19 Might Reduce Future Drug Spending
A positive outcome of the pandemic may be the demonstration via emergency measures that state governments can be flexible in substitution policies.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
By Ameet Sarpatwari, Charlie Lee, Frazer Tessema, and Aaron S. Kesselheim Each month, members of the Program On Regulation, Therapeutics, And Law (PORTAL) review the peer-reviewed medical literature to identify interesting empirical studies, policy analyses, and editorials on health law and policy issues relevant to current or potential future work in the Division.
